Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 7Thoracic 4Sarcoma 2Endocrine 2CNS 2Breast 2Plasma cell 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Suramin × Thoracic × Clear all
NCT01671332 2020-05-12

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

University of Wisconsin, Madison

Phase 2 Completed
80 enrolled 13 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01038752 2015-05-21

Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer

Optimum Therapeutics, LLC

Phase 2 Terminated
14 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00006929 2013-06-04

Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00066768 2013-06-04

Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡